DOCSLIB.ORG

IPR Biotech April 2009

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IPR Biotech April 2009 WISTA APRIL 2009 From the Desk of Chairman IPR Biotechnology : Part 8 - 56 RNA splicing is the process in which introns, or intervening sequences within a gene, are removed from RNA prior to translation of RNA into protein. RNA splicing takes place in the nucleus of a cell where DNA transcription occurs. There are many types of splicing mechanisms, one of them involves the splicesome, an array of proteins that function to splice out introns. The proteins serve to initiate, stabilize, and break the RNA-RNA interactions forming during the process. The splicing pattern determines the delivery of genetic information and the nature of the final protein product. The information could be used to predict the genetic mutations potentially responsible for causing disease. The Special Feature in the current issue of WISTA:IPR Biotechnology deals with RNA splicing, its mechanism and clinical significance. It also briefly describes some of the recent patents on RNA splicing and related aspects in the field. 'On to Excellence' profiles Acrongenomics Inc, Geneva, a publicly traded research and development nanotechnology company, pioneering the development of uniquely advanced nano-molecular diagnostics for life sciences. It offers innovative and realistic concepts capable of creating viable, low cost and portable point-of-care diagnostic devices for medical testing. Arsenic is a highly toxic element and may pose health risk to humans. However, some microorganisms can tolerate relatively high concentrations of the metalloid. Researchers have found an algae that detoxifies arsenic, thus potentially discovering a possible way for cleaning up underground water, particularly in such affected areas as parts of West Bengal and Bangladesh. The 'Perspective' covers the algae capable of detoxifying arsenic. Other features covered in this issue are: Scan Around the Globe; Watch-Out IPR; In Focus; Strategic Alliances; Clinical Trials; Awards; and Legal Scene. We welcome comments and suggestions. Dr K V Swaminathan CONTENTS RESEARCH & ANALYSIS TEAM • From the Desk of Chairman [P 2 ] Dr Shelley Lahiri Consultant • Scan Around the Globe: Bionic Eye (Australia); New Biologics Pilot Plant (Belgium); Hepavax-Gene (China); Marketing Authorisation for Valdoxan (France); Innovation Mr B K Wadhawan Director Award for Narion (Germany); Brain's Reserve Cells (Sweden); Stiffening Arteries (USA) [P 3 - 4] Mr S S Kalra Director • Watch-Out IPR: Antibody-Based Therapeuties; ATPace Formulation Patent; Japanese Patent for Invisicare; Monoclonal Antibody; Patents on AtherOx® Technology; This publication aims at Recombinant Protein Process. [P 5 - 6] disseminating information on pertinent developments in its • Perspective: Aglae Detoxifies Arsenic. [P 7] specific field of coverage. The • In Focus: Culturing HEK 293 Cells; Drugs Using New Biosensor; GenNext Cancer information published does not, Treatment; Nanoparticles Light Up Tumors; Stem Cells Control Knobs; Stem-Cell Niche therefore, imply endorsement of Model. [P 8 - 9] any product/process/producer or • Strategic Alliances: Agreementm on Vaccines for HIV and Malaria; Antibody technology by WITT. Optimization Collaboration; Business Merger Agreement; License for Asthma Discovery; Licensing Tie-Up; Ligand and Rockefeller Settle Dispute; Vaccine Adjuvant Editor : Dr K V Swaminathan R & D Collaboration; Zinc Finger Nucleases. [P 10 - 11] Printed and Published by • On To Excellence: Acrongenomics, Inc. [ P 12 ] Dr K V Swaminathan, on behalf of Waterfalls Institute of Technology • Special Feature: RNA Splicing. [P 13 - 15] Transfer, J-29 South Extension Part I, • Clinical Trials: BETAS Safety Trial Results; Phase II Trial of Tb-402. [P 16] New Delhi - 110 049. • Awards: Novo Nordisk Prize; Top Research Partner Award. [P 16] • Fine Tuning: Diseases vs Bactrial Genes. [P 17] Printed at Sagar Printers, 1880 Udaichand Marg, • Legal Scene: Fosrenal Lawsuit; Illumina Suit Against DNAPrint; Infringement Action; Legislation to Boost Clinical Trials; Skelaxin Patent Invalidated; Suit Against Kotla Mubarakpur, Teva; Warner Chilcott Infringement Lawsuit. [P 18 - 19] New Delhi -110 003. VOL 10 ISSUE 10 1 IPR BIOTECHNOLOGY SEC 2 WISTA APRIL 2009 for its biological compounds under development, SCAN AROUND THE GLOBE extending its knowledge and competencies in this field. (Belgium - UCB, Inc., Feb 19, 2009) Bionic Eye Hepavax-Gene Australian consortium announced that tens of thousands of people with severe vision loss are The Chief Executive Officer (CEO) of Chinese set to benefit after the formation of a landmark company, Crucell N V, announced that the Chinese partnership of world-leading Australian research authorities have released Hepavax-Gene®, institutes. Bionic Vision Australia will pursue the a recombinant hepatitis B vaccine, for registration development of the most technologically advanced and quality control in China. According to the CEO, bionic eye to improve the sight of people with the launch of Hepavax-Gene® is a significant degenerative or inherited retinal disease. advancement in the expansion of Crucell’s business in the highly strategic Chinese vaccine market. This Bionic Vision Australia’s members include the hepatitis B vaccine will contribute significantly to the University of Melbourne, the University of New sustainability of Chinese operations. The Chinese South Wales, the Bionic Ear Institute, Centre for Eye hepatitis B vaccine market is the world’s biggest Research Australia and the Victoria Research market with approximately 100 million doses Laboratory of NICTA. administered yearly. According to the chairman of the Bionic Vision According to the company, the prospects for Australia, their research team is well placed to Hepavax-Gene® in the Chinese private market are undertake the critical research required to deliver an excellent. Hepavax-Gene® will be positioned in the advanced Bionic Eye, which would improve quality high-end private market segment with a particular of life for patients suffering from common causes focus on young adults. Hepavax-Gene® possesses of severe loss of vision and blindness. two decisive advantages: its production is based on Crucell’s hansenula polymorpha patented technology A bionic eye will assist in restoring patient and it is 100% free of thiomersal. Thiomersal is a mobility by effectively replacing the function of mercury based compound which, in several countries, damaged light-sensing cells in the eye. While the clarity is being phased out from vaccines given to children and definition of vision will not be equal to normal to avoid potentially adverse effects. sight, the device will allow patients to move around, detect large objects and, in time, read text and (China-Crucell N V, Dec 10, 2008) recognise faces and emotions. Marketing Authorisation for Valdoxan (Australia - Bionity.Com, Nov 14, 2008) France’s leading independent pharmaceutical company. Servier, discovered and developed New Biologics Pilot Plant Valdoxan (R)/ Thymanx (R), the first melatonergic UCB Inc., Brussels, Belgium, is a biopharmaceutical antidepressant for the treatment of adult patients company dedicated to research, development with major depressive episodes. The European and commercialization of innovative medicines with a Commission has granted marketing authorization focus on the fields of central nervous system and for Servier’s Valdoxan. immunology disorders. The company announced its The European approval of Valdoxan is based on plans to build a biologics pilot plant on its site in both short and long-term results from a large Braine-1’Alleud, Belgium. Company’s pilot plant comprehensive, international development programme is expected to become operational early 2012. including almost 6,000 adult patients with The biologics pilot plant will allow UCB depression. The results demonstrate the superior to further optimise the bio-manufacturing processes efficacy of Valdoxan. IPR BIOTECHNOLOGY 2 WISTA APRIL 2009 Following approval from the European so-called Notch signaling pathway, which inhibits Commission, Valdoxan is expected to become the creation of new nerve cells. commercially available in European countries. (Sweden - Karolinska Instetutet, Feb 24, (France- PRNewswire, Jan 24, 2009) 2009) Innovation Award for Nanion Stiffening Arteries Nanion is a well known organized company. Scientists across Cornell are involved in the effort According to CTO of Nanion, to remain a profitable to combat heart disease and stroke in a variety of and leading provider of advanced and high ways, from investigating its causes and contributing quality ion channel drug screening system, the factors to testing possible pathways for treatments. company constantly seeks new inventions and Like skin that loses elasticity, blood vessels lose solutions that are attractive to industrial and their pliability and stiffen with age. In more than half academic institutions. of the US population over 65, this stiffening of the blood vessels is accompanied by a buildup of plaque The German Industry’s Innovation Award, also inside arterial walls - atherosclerosis - which can lead the world’s first innovation award, has since 1980 to blood vessel obstruction, increased stress on the annually nominated and rewarded the nation’s most heart and the risk of a heart attack. Researchers important scientific and technical innovations. Nanion have long known that factors like smoking and is one of the five remaining candidates for the award. high cholesterol intake contribute to the disease. But Nanion was nominated for an innovation
Load more

Recommended publications
  • Comment Letter
    July 23, 2008 Subject: Follow-up on July 22 Meeting Dr. Sirri et al.: I thank you for meeting with Ken Salomon, John Welborn and me yesterday afternoon to discuss Reg SHO, naked short selling and the SEC's recent emergency order. As a follow-up, I want to emphasize the following points: 1. OSTK continues to believe that it is critical that the SEC extend the pre-borrow requirement of the emergency order to the entire market, not just the 19 select companies. OSTK requests that the SEC promptly undertake swift rulemaking so that this protection applies fairly across the market. 2. OSTK continues to support the prompt and full elimination of the option market maker exception, an exception that swallows up the good intentions of Reg SHO. During yesterday's meeting, we discussed the relationship between the markets for equities and their corresponding derivatives (including listed options). You stated that options market makers enjoy an exception from the Reg SHO requirement that they locate and/or deliver shares when hedging against options positions. I am not sure that I would read Reg SHO to say that. However, under your theory, if an options market maker sells a put with a 6- month expiration, then that same market maker has the legal right to naked short and fail to deliver an equivalent amount of the underlying equity (leaving the option market maker "delta neutral”) for six months. This exception is unnecessary and open to abuse/manipulation, particularly with the married puts that often occur in Reg SHO threshold securities.
    [Show full text]
  • [ Emc-Lusinnufll'lergcrta'rgets
    US 20070255633Al (19) United States (12) Patent Application Publication (10) Pub. N0.: US 2007/0255633 A1 Kridel (43) Pub. Date: NOV. 1, 2007 (54) SYSTEMS AND METHODS FOR INVESTING (52) US. Cl. ....................................................... .. 705/35 (76) Inventor: FIVJigiam J. Kridel, New York, NY (57) ABSTRACT The present invention discloses systems and methods for Correspondence Address? creating and managing ?nancial instruments and indexes PAUL’ HASTINGS’ JANOFSKY & WALKER comprised of securities for companies in subsectors of the LLP economy. These ?nancial instruments alloW investment in R0' BOX 919092 subsectors of the economy Will still being able to minimize SAN DIEGO CA 92191-9092 ’ risk by diversi?cation. The indexes serve as benchmarks for (21) App1_ NO; 11/465,768 companies in the subsectors of the economy. A procedure may be used to identify the securities to include in the (22) Filed: Allg- 18, 2006 ?nancial instruments. This procedure may include (a) iden _ _ tifying securities for companies in a sector of the economy; Related U's‘ Apphcatlon Data (b) limiting the identi?ed securities to those for companies (60) Provisional application No. 60/778,492, ?led on Mar. in a SubSeCIOr Of the SBCIOI‘ Of the economy; (0) applying 1, 2006. focus rules to further limit the identi?ed securities to those _ _ _ _ for companies Who are focused in the subsector of the Pubhcatlon Classl?catlon economy; and (d) limiting the securities included in the (51) Int, Cl, ?nancial instrument or index to those that satisfy other G06Q 40/00 (2006.01) objective criteria. ETF RULE. SET->| APPLICATION’ ' "1 _.
    [Show full text]
  • Memorandum To
    MEMORANDUM TO: File No. S7-20-08; Securities Exchange Act Release No. 58190 FROM: Division of Trading and Markets DATE: July 31, 2008 RE: Meeting on Securities Exchange Act Release No. 34-58166 On July 22, 2008, staff of the Division of Trading and Markets met with representatives from Overstock.com, Inc. to discuss Regulation SHO, “naked” short selling, and the Commission’s recent Emergency Order, (Securities Exchange Act Release No. 34- 58166). Overstock followed-up this meeting by sending an e-mail attaching a letter which is included as an attachment to this Memorandum. July 23, 2008 Subject: Follow-up on July 22 Meeting Dr. Sirri et al.: I thank you for meeting with Ken Salomon, John Welborn and me yesterday afternoon to discuss Reg SHO, naked short selling and the SEC's recent emergency order. As a follow-up, I want to emphasize the following points: 1. OSTK continues to believe that it is critical that the SEC extend the pre-borrow requirement of the emergency order to the entire market, not just the 19 select companies. OSTK requests that the SEC promptly undertake swift rulemaking so that this protection applies fairly across the market. 2. OSTK continues to support the prompt and full elimination of the option market maker exception, an exception that swallows up the good intentions of Reg SHO. During yesterday's meeting, we discussed the relationship between the markets for equities and their corresponding derivatives (including listed options). You stated that options market makers enjoy an exception from the Reg SHO requirement that they locate and/or deliver shares when hedging against options positions.
    [Show full text]
  • Board of Directors Meeting
    BOARD OF DIRECTORS MEETING December 15, 2016 CSIS Building WASHINGTON, D.C. PERSONALIZED MEDICINE COALITION BOARD MEETING December 15, 2016 10:00 a.m. to 2:00 p.m. CSIS Building Washington, D.C. 9th Floor Turret Room Agenda Chairman’s Report 1. Approval of May 25, 2016 Minutes 2. Nominations Committee President’s Report 3. 2016 Progress Report 4. Plans for 2017 5. Finance and Budget 6. Membership 7. Public Policy 8. Science Policy 9. Communications New Business December 2016 Board Meeting Table of Contents Agenda 1. Minutes – May 25, 2016 2. Nominations • Current Board Members • Board Composition by Category • Board of Directors Duties • Bylaws 3. Progress Report • 2016 Progress Report • Conference Program (back pocket) 4. Plans for 2017 • Strategic Plan for 2017 • Clinical and Economic Value of Next-Generation Sequencing • The Personalized Medicine Education Initiative • International Comparative Landscape Analysis • Evidence for Coverage and Payment of Personalized Medicine Diagnostics • Personalized Medicine in Value Assessment Frameworks • Turning the Tide Against Cancer 2017 Conference Prospectus • CRD Proposal: Public Policy • Jen Leib Biography • PMC Vice President, Public Policy: Job Description • Kayla Smith Resume 5. Finance and Budget • 2017 Budget • Historical Budget • 2016 Sponsorships • Friends of PMC • Cash and Investments • Chart: Revenues & Expenses • Chart: Membership & Financial Performance • Chart: Cumulative Net Assets • Investment Detail 6. Membership Status • Chart: PMC Membership Numbers • Dues Schedule for Members and Sponsors • Organizations that have withdrawn from PMC since 2007 • Chart: Analysis of 2015 and 2016 Membership Non-Renewal by Reason • 2016 and 2017 New Members • Target List for 2017 Membership • List of PMC Members • Chart: PMC Membership Numbers by Category • 2016 Sponsorships 7.
    [Show full text]
  • The Commercial & Clinical Development of Pharmacogenetics
    TheFalse commercial Positive? & clinical development of pharmacogenetics Paul Martin, Graham Lewis, Andrew Smart & Andrew Webster False positive? The clinical and commercial development of pharmacogenetics Paul Martin IGBiS, University of Nottingham Graham Lewis SATSU, University of York Andy Smart Bath Spa University Andrew Webster SATSU, University of York Acknowledgements This research was supported by a Wellcome Trust Biomedical Ethics programme project award (Ref No: 018381) on The Clinical and Commercial Development of Pharmacogenetics held by Paul Martin (Principal Investigator), Alison Pilnick and Andrew Webster. The original research was carried out between 2001-03, but data in this report has been updated with data collected as part of the authors’ involvement in the following projects: 1) A study Realising the Potential of Genomic Medicine undertaken by Paul Martin and Michael Morrison funded by the Royal Pharmaceutical Society; 2) A recent ESRC Science in Society Programme project undertaken by Graham Lewis (Pharmacogenomics, diagnostic tests and clinician acceptance, Award No. RES-151-25-0049) for which he is Principal Investigator; 3) A European Commission funded report: Institute for Prospective Technological Studies (IPTS) (2005) Pharmacogenetics and Pharmacogenomics: state-of-the-art and potential socio-economic impacts in the EU. European Commission Joint Research Centre, Seville, Spain. In particular, some of the data in chapters 2 and 3 were collected as part of this work by Paul Martin and Graham Lewis. The authors would like to acknowledge the support of the following people who have helped in the management and execution of the project: Dr Alison Pilnick who was involved in establishing the project and advising on the drug case studies; Katie Coveny and Michael Morrison who helped update the industry analysis; and Martyn Pickersgill who drafted the executive summary.
    [Show full text]
  • Annotated Scholarly Guide to the HGP
    The Human Genome Project: An Annotated & Interactive Scholarly Guide to the Project in the United States Editor: Kevin Davies Cold Spring Harbor Laboratory Library & Archives The Human Genome Project: An Annotated & Interactive Scholarly Guide to the Project in the United States Editor Kevin Davies Project Leaders Ludmila Pollock Judy Wieber Production Manager Thomas Adams Contributors Brian Dick Robert Wargas Michael Eisenstein Victor McElheny Stephanie Satalino Reviewers Jan Witkowski Rick Myers Robert Cook-Deegan Acknowledgment This project was supported by the National Library of Medicine (NLM) Grants for Scholarly Works in Biomedicine and Health (G13). Project Title: Human Genome Project Documentary History: An Annotated Scholarly Guide to the HGP. PI: Ludmila Pollock Research reported in this publication was supported by the National Library of Medicine of the National Institutes of Health under Award Number G13LM011890-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Copyright © 2016 Cold Spring Harbor Laboratory. All rights reserved. Researched, compiled and published by Cold Spring Harbor Laboratory Library & Archives. All World Wide Web addresses are accurate to the best of our knowledge at the time of the printing. ISBN 978-0-9978662-0-9 Extracted: 2016-11-22 INTRODUCTION - 2 The Human Genome Project: An Annotated & Interactive Scholarly Guide to the Project in the United States 1 INTRODUCTION It is my great pleasure to introduce The Human Genome Project: An Annotated & Scholarly Guide to the Project in the United States. The idea for this annotated scholarly guide to the Human Genome Project (HGP) originated at an international meeting on the history of the HGP that was held in May of 2012 at the Cold Spring Harbor Laboratory’s Banbury Center.
    [Show full text]
  • File Name: Williamsjensen021706.Pdf
    WILLIAMS & JENSEN, PLLC TELEPHONE SUITE 300 FACSIMILE (202) 659-8201 1155 21ST STREET,N.W. (202) 659-5249 WASHINGTON, D.C. 20036-3308 February 17,2006 Ms. Nancy M. Morris Secretary Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-9303 Re: Definition of Eligible Portfolio Company under the Investment Company Act of 1940; File No. S7-37-04 Dear Ms. Morris: This submission provides updated and additional data to support the Commission's efforts to modernize the definition of "eligible portfolio company" under the Investment Company Act of 1940. We continue to hear from business development companies (BDCs) regarding the absence of a meaningful and relevant standard for the definition of "eligible portfolio company." We hope that the Commission will examine the attached data and adopt a rule that modernizes the definition in a meaningful fashion, or alternatively urges Congress to remedy the problem through corrective legislation. An effective definition must provide sufficient access for the smaller- and middle-tier public companies that otherwise have little or no access to the public capital markets and also investment opportunities fox-the benefit of BDC shareholders. In 2004, Congress began to address the need to modernize the definition of "eligible portfolio company." The BDC industry pursued a legislative solution because the staff of the Division of Investment Management had indicated in earlier discussions with representatives of the BDC industry that a legislative remedy was the best course of action. The Investment Company Act defines "eligible portfolio company" to include those public companies that do not have outstanding securities upon which margin credit can be granted consistent with the Federal Reserve Board's margin rules.
    [Show full text]
  • Integrating Pharmacogenetics Into Society: in Search of a Model
    F OCUS ON PHARMACOGENETICS 29. Jones, B. C. et al. Quantitative-trait loci Acknowledgements and selling a range of specialist services to analysis of cocaine-related behaviours and Supported by National Institutes of Health grants. neurochemistry. Pharmacogenetics 9, 607–617 the pharmaceutical industry. This core Competing interests statement (1999). group is described in TABLE 1.Most of these 30. Port, J. D. & Bristow, M. R. Altered β-adrenergic The author declares no competing financial interests. receptor gene regulation and signaling in chronic heart firms have been formed since 1997 and are failure. J. Mol. Cell Cardiol. 33, 887–905 Online Links mainly located in the United States. Between (2001). 31. van Campen, L. C., Visser, F. C. & Visser, C. A. DATABASES 1997 and 2000, there was a steady growth in Ejection fraction improvement by β-blocker treatment The following terms in this article are linked online to: in patients with heart failure: an analysis of studies Entrez Gene: http://www.ncbi.nlm.nih.gov/entrez/ the number of small to medium enterprises published in the literature. J. Cardiovasc. Pharmacol. query.fcgi?db=gene working with PGx. However, in 2001 this 32 Suppl. 1, S31–S35 (1998). ADRB1 | ADRB2 | CFTR | CYP1A2 | CYP2D6 | CYP2E1 | 32. Mason, D. A., Moore, J. D., Green, S. A. & CYP3A4 | TPMT | growth slowed, and in 2002 consolidation of Liggett, S. B. A gain-of-function polymorphism in a OMIM: http://www.ncbi.nlm.nih.gov/entrez/ the sector started to take place, with five β query.fcgi?db=OMIM G-protein coupling domain of the human 1- adrenergic receptor.
    [Show full text]